Atomwise is a leading artificial intelligence (AI) drug discovery company in San Francisco, CA. We develop and use patented AI technology to help companies and universities develop therapies that will improve human health and agricultural productivity. Atomwise believes you do your best work when you’re on a team that values your contributions.
We’re looking for candidates who have experience in biology or biochemistry to manage assay selection for our drug discovery pipeline. This is an exciting position on our production team with the potential for growth and advancement.
Atomwise is an equal opportunity employer and strives to foster an inclusive workplace. Our mission is to develop better medicines faster, and we know that we need a diverse team to develop medicines that serve diverse populations. Accordingly, Atomwise does not make any employment decisions (including but not limited to, hiring, compensation, and promotions) on the basis of race, religion, color, national origin, gender, gender identity, sexual orientation, age, veteran status, disability status, or any other characteristics protected by applicable federal, state, and local law.
We strongly encourage people of diverse backgrounds and perspectives to apply.
Atomwise is not currently offering visa sponsorships for any position. Please only apply if eligible to work in the U.S.
Pursuant to the San Francisco Fair Chance Ordinance, we will consider for employment qualified applicants with arrest and conviction records.
Atomwise Inc. patented the first deep learning technology for structure-based small molecule drug discovery. This AI technology harnesses millions of data points and thousands of protein structures to solve problems that a human chemist would take many lifetimes to solve. Atomwise has partnered with some of the world's largest pharmaceutical and agtech companies and with more than 100 leading academic institutions and hospitals, to tackle the challenges of discovering and developing better drugs and agrochemicals. Atomwise has raised over $50 million from leading venture capital firms to support the development and application of its AI technology.